1. |
- Köhler, Th., et al.
(author)
-
Precision measurement of strong interaction isotope effects in antiprotonic 16O, 17O, and 18O atoms
- 1986
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 176:3-4, s. 327-333
-
Journal article (peer-reviewed)abstract
- The strong-interaction effects in antiprotonic 16O, 17O, and 18O atoms were measured at the CERN antiproton facility, LEAR. The shifts ε{lunate} and the widths Γ of the 3d level were determined to be -112±20 eV (16O), -140±46 eV (17O), -195±20 eV (18O), and 495±45 eV (16O), 540±150 (17O), 640±40 eV (18O), respectively. © 1986.
|
|
2. |
|
|
3. |
- Guigas, R., et al.
(author)
-
Strong interaction effects in antiprotonic 6Li/7Li atoms
- 1984
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 137:56, s. 323-328
-
Journal article (peer-reviewed)abstract
- The effects of strong interaction on the 3 –> 2 X-ray transition in antiprotonic 6Li/7Li atoms have been measured at the low energy -beam at CERN. For the shifts and widths of the levels the values [epsilon]2p = (-230 ï¿œ 72) eV, [Gamma]2p = (443 ï¿œ 210) eV, and [Gamma]3d = (0.130 ï¿œ 0.045) eV for 6Li, and [epsilon]2p = (-336 ï¿œ 60) eV, [Gamma]2p = (456 ï¿œ 190) eV, and [Gamma]3d = (0.210 ï¿œ 0.062) eV for 7Li were found. The data are compared with optical model predictions.
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
- Adiels, Lars, 1952-, et al.
(author)
-
Test of CP violation with K0 and K‾0 at LEAR
- 1985
-
In: Physics with antiprotons at LEAR in the ACOL era. - Gif sur Yvette : Editions Frontières. - 2863320351 ; , s. 467-482
-
Conference paper (other academic/artistic)
|
|
9. |
|
|
10. |
- Ankerst, Jaro, et al.
(author)
-
Complete remission in a patient with acute myelogenous leukemia treated with leukocyte α-interferon and cimetidine
- 1984
-
In: Cancer Immunology Immunotherapy. - 0340-7004. ; 17:1, s. 69-71
-
Journal article (peer-reviewed)abstract
- A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no tendency to increased binding to remission cells. The aim of this report is to stimulate a further evaluation of this form of therapy in additional AML patients whenever this might be justified as an alternative to conventional chemotherapy.
|
|